Review
Year 2024,
Volume: 63 Issue: 1, 151 - 156, 19.03.2024
Abstract
Sakral nöromodülasyon uygulamaları; aşırı aktif mesane, kronik üriner retansiyon, interstisyel sistit, fekal inkontinans ve kronik kabızlık gibi pek çok konservatif tedaviye dirençli kronik pelvik ağrı tedavisinde kullanılabilen etkin tedavi seçenekleridir. Kronik ağrıda nörostimülasyon uygulamaları giderek popüler hale gelmiştir. Aşırı aktif mesane tedavisinde sakral nöromodülasyon uygulamaları % 61 ile 90 arasında değişen oranda fayda göstermektedir. Sakral nöromodülasyon uygulaması iki aşamadan oluşur; ilk aşama deneme (trial) periyodu, ikinci aşama ise kalıcı pil yerleştirilmesidir. Gelişen teknoloji ile birlikte daha küçük boyutlu, manyetik rezonans görüntüleme uyumlu ve sarj edilebilir stimülatör seçenekleri ortaya çıkmıştır. Bu hastalar multidisipliner yaklaşımla ele alınmalı ve tedavi buna göre planlanmalıdır. Bu derlemede aşırı aktif mesane tedavi yönetiminde sakral nöromodülasyon uygulamaları literatür rehberliğinde anlatılmaktadır.
Supporting Institution
yok
Project Number
yok
Thanks
yok
References
- Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78
- Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20 (6):327-36.
- Chuang YC, Liu SP, Lee KS, et al. Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study. Low Urin Tract Symptoms. 2019;11(1):48-55.
- Lightner DJ, Gomelsky A, Souter L,et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3):558-563.
- Chen LC, Kuo HC. Pathophysiology of refractory overactive bladder. Low Urin Tract Symptoms. 2019;11(4):177-81.
- Jiang YH, Wang CC, Kuo HC. Videourodynamic findings of lower urinary tract dysfunctions in men with persistent storage lower urinary tract symptoms after medical treatment. PLoS One. 2018 Feb 20;13(2):e0190704. doi: 10.1371/journal.pone.0190704. PMID: 29462145; PMCID: PMC5819762.
- Fan YH, Lin AT, Chen KK. Defining causes for overactive bladder symptoms in women. Low Urin Tract Symptoms. 2012;4(2):73-6.
- Ponholzer A, Temml C, Wehrberger C, et al. The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur Urol. 2006;50(3):581-86.
- Malaguti S, Spinelli M, Giardiello G,et al. Neurophysiological evidence may predict the outcome of sacral neuromodulation. J Urol. 2003;170(6 Pt 1):2323-26.
- Önem K, Aşırı Aktif Mesane’de Sakral Nöromodülasyona Dair A’dan Z’ye Bilinmesi Gerekenler Kontinans ve Nöroüroloji Bülteni 2016; 3: 84-96
- Lo CW, Wu MY, Yang SS, et al. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis. Toxins (Basel). 2020 Feb 18;12(2):128.
- Chughtai, B., Clemens, J. Q., Thomas, D.et al. Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost. The Journal of urology 2020, 203(1), 179–84.
- Tay LJ, Harry D, Malde S, et al. Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder. Urology. 2021 Mar;149:1-10. doi: 10.1016/j.urology.2020.11.018. Epub 2020 Nov 20. PMID: 33227305.
- Zhang Y, Ji F, Liu E, et al. Mechanism and Priority of Botulinum Neurotoxin A versus Sacral Neuromodulation for Refractory Overactive Bladder: A Review. Urol Int. 2021;105(11-12):929-934. doi: 10.1159/000515991. Epub 2021 Jun 15. PMID: 34130295.
- Amin K, Moskowitz D, Kobashi KC, et al. Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation? J Urol. 2019 May;201(5):973-78.
- High RA, Winkelman W, Panza J,et al. Sacral neuromodulation for overactive bladder in women: do age and comorbidities make a difference? Int Urogynecol J. 2021 Jan;32(1):149-157. doi: 10.1007/s00192-020 04392-4. Epub 2020 Jun 25. PMID: 32588075.
- Siegel S, Kreder K, Takacs E, et al. Prospective randomized feasibility study assessing the effect of cyclic sacral neuromodulation on urinary urge incontinence in women. Female Pelvic Med Reconstr Surg. 2018;24(4):267–71.
- de Oliveira PS, Reis JP, de Oliveira TR, et al.The Impact of Sacral Neuromodulation on Sexual Dysfunction. Curr Urol. 2019 Jul;12(4):188-94.
- Khunda A, McCormick C, Ballard P. Sacral neuromodulation and sexual function: a systematic review and meta-analysis of the literature. Int Urogynecol J. 2019 Mar;30(3):339-52.
- De Wachter S, Knowles CH, Elterman DS, et al. New Technologies and Applications in Sacral Neuromodulation: An Update. Adv Ther. 2020 Feb;37(2):637-43.
- Cohn JA, Kowalik CG, Kaufman MR, et al. Evaluation of the axonics modulation technologies sacral neuromodulation system for the treatment of urinary and fecal dysfunction. Expert Rev Med Devices. 2017;14(1):3–14.
- Jabri A, Laiq Z, Nabeel Y. Twiddler’s syndrome: an unusual cause of repeated shocks by implantable cardioverter-defibrillator in an asymptomatic patient. Heart Views. 2019;20(3):118–21.
- Jin J, Sklar GE, Min Sen OhV, et al. Factors affecting therapeutic compliance: a review from the patient’s perspective. Ther Clin Risk Manag. 2008;4(1):269–86.
- Tutolo M, Ammirati E, Van der Aa F. What Is New in Neuromodulation for Overactive Bladder? Eur Urol Focus. 2018 Jan;4(1):49-53.
Year 2024,
Volume: 63 Issue: 1, 151 - 156, 19.03.2024
Abstract
Sacral neuromodulation is an effective treatment modality for chronic pelvic pain refractory to conventional treatments such as overactive bladder, chronic urinary retention, interstitial cystitis, fecal incontinence and chronic constipation. There is growing interest in the use of neuromodulation for chronic pain. Sacral neuromodulation has been shown to provide benefits ranging from 61% to 90% in the treatment of overactive bladder. Sacral neuromodulation is a two-step process that includes a trial period in the first step and the placement of a permanent battery in the second step. Due to the complexity of this treatment, a multidisciplinary approach is required for optimal patient management. As technology evolves, smaller, magnetic resonance imaging compatible, and rechargeable stimulator options have been developed. The treatment approach should be planned accordingly. In this review, we discuss the application of sacral neuromodulation in the management of overactive bladder with reference to the literature.
Project Number
yok
References
- Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78
- Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20 (6):327-36.
- Chuang YC, Liu SP, Lee KS, et al. Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study. Low Urin Tract Symptoms. 2019;11(1):48-55.
- Lightner DJ, Gomelsky A, Souter L,et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3):558-563.
- Chen LC, Kuo HC. Pathophysiology of refractory overactive bladder. Low Urin Tract Symptoms. 2019;11(4):177-81.
- Jiang YH, Wang CC, Kuo HC. Videourodynamic findings of lower urinary tract dysfunctions in men with persistent storage lower urinary tract symptoms after medical treatment. PLoS One. 2018 Feb 20;13(2):e0190704. doi: 10.1371/journal.pone.0190704. PMID: 29462145; PMCID: PMC5819762.
- Fan YH, Lin AT, Chen KK. Defining causes for overactive bladder symptoms in women. Low Urin Tract Symptoms. 2012;4(2):73-6.
- Ponholzer A, Temml C, Wehrberger C, et al. The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur Urol. 2006;50(3):581-86.
- Malaguti S, Spinelli M, Giardiello G,et al. Neurophysiological evidence may predict the outcome of sacral neuromodulation. J Urol. 2003;170(6 Pt 1):2323-26.
- Önem K, Aşırı Aktif Mesane’de Sakral Nöromodülasyona Dair A’dan Z’ye Bilinmesi Gerekenler Kontinans ve Nöroüroloji Bülteni 2016; 3: 84-96
- Lo CW, Wu MY, Yang SS, et al. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis. Toxins (Basel). 2020 Feb 18;12(2):128.
- Chughtai, B., Clemens, J. Q., Thomas, D.et al. Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost. The Journal of urology 2020, 203(1), 179–84.
- Tay LJ, Harry D, Malde S, et al. Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder. Urology. 2021 Mar;149:1-10. doi: 10.1016/j.urology.2020.11.018. Epub 2020 Nov 20. PMID: 33227305.
- Zhang Y, Ji F, Liu E, et al. Mechanism and Priority of Botulinum Neurotoxin A versus Sacral Neuromodulation for Refractory Overactive Bladder: A Review. Urol Int. 2021;105(11-12):929-934. doi: 10.1159/000515991. Epub 2021 Jun 15. PMID: 34130295.
- Amin K, Moskowitz D, Kobashi KC, et al. Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation? J Urol. 2019 May;201(5):973-78.
- High RA, Winkelman W, Panza J,et al. Sacral neuromodulation for overactive bladder in women: do age and comorbidities make a difference? Int Urogynecol J. 2021 Jan;32(1):149-157. doi: 10.1007/s00192-020 04392-4. Epub 2020 Jun 25. PMID: 32588075.
- Siegel S, Kreder K, Takacs E, et al. Prospective randomized feasibility study assessing the effect of cyclic sacral neuromodulation on urinary urge incontinence in women. Female Pelvic Med Reconstr Surg. 2018;24(4):267–71.
- de Oliveira PS, Reis JP, de Oliveira TR, et al.The Impact of Sacral Neuromodulation on Sexual Dysfunction. Curr Urol. 2019 Jul;12(4):188-94.
- Khunda A, McCormick C, Ballard P. Sacral neuromodulation and sexual function: a systematic review and meta-analysis of the literature. Int Urogynecol J. 2019 Mar;30(3):339-52.
- De Wachter S, Knowles CH, Elterman DS, et al. New Technologies and Applications in Sacral Neuromodulation: An Update. Adv Ther. 2020 Feb;37(2):637-43.
- Cohn JA, Kowalik CG, Kaufman MR, et al. Evaluation of the axonics modulation technologies sacral neuromodulation system for the treatment of urinary and fecal dysfunction. Expert Rev Med Devices. 2017;14(1):3–14.
- Jabri A, Laiq Z, Nabeel Y. Twiddler’s syndrome: an unusual cause of repeated shocks by implantable cardioverter-defibrillator in an asymptomatic patient. Heart Views. 2019;20(3):118–21.
- Jin J, Sklar GE, Min Sen OhV, et al. Factors affecting therapeutic compliance: a review from the patient’s perspective. Ther Clin Risk Manag. 2008;4(1):269–86.
- Tutolo M, Ammirati E, Van der Aa F. What Is New in Neuromodulation for Overactive Bladder? Eur Urol Focus. 2018 Jan;4(1):49-53.
There are 24 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Pain |
| Journal Section | Reviews |
| Authors | |
| Project Number | yok |
| Publication Date | March 19, 2024 |
| Submission Date | August 8, 2023 |
| Published in Issue | Year 2024Volume: 63 Issue: 1 |
